PROSTA-LUX

CLINICAL STUDIES ON THE FOLLOWING INGREDIENTS:

Saw Palmetto

Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia*

Abstract

Benign prostatic hyperplasia (BPH) is a noncancerous growth of the prostate. BPH commonly occurs in elderly men. Lower urinary tract symptoms (LUTS) secondary to BPH (LUTS/BPH) have significant impacts on their health. Saw palmetto (Serenoa repens) extract (SPE) has been evaluated for its effectiveness in improvement of LUTS/BPH at preclinical and clinical levels. Potential mechanisms of actions include anti-androgenic, pro-apoptotic, and anti-inflammatory effects. However, SPE efficacy was inconsistent, at least partly due to a lack of a standardized SPE formula. A hexane extract (free fatty acids, > 80%) provided more consistent results. Free fatty acids (lauric acid) were effective in inhibition of 5α-reductase, and phytosterol (β-sitosterol) reduced prostatic inflammation. Multiple actions derived from different constituents may contribute to SPE efficacy. Evaluation of the clinical relevance of these bioactive components is required for standardization of SPE, thereby enabling consistent efficacy and recommendations for the use in the prevention and treatment of BPH.

Source: Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol. 2019 Apr 17;28(6):1599-1606. doi: 10.1007/s10068-019-00605-9. PMID: 31807332; PMCID: PMC6859144.

The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study*

Abstract

Because prostatic surgery is not the treatment of choice for most patients with benign prostatic hyperplasia (BPH), the therapeutic effect of a 160-mg, twice-daily, oral dose of Serenoa repens extract was studied during a 3-month open trial in 505 patients with mild-to-moderate symptoms of BPH. The efficacy of the regimen was evaluated in 305 of these patients. Traditional parameters for quantifying prostatism, such as the International Prostate Symptom Score, the quality of life score, urinary flow rates, residual urinary volume, and prostate size, were found to be significantly improved after only 45 days of treatment. After 90 days of treatment, a majority of patients (88%) and treating physicians (88%) considered the therapy effective. In addition, the serum prostate-specific antigen concentration was not modified by the drug, thus limiting the risk of masking any possible development of prostate cancer during treatment. The incidence of side effects (5%) was low and compares favorably with that reported for existing medical therapies used in BPH patients. The extract of Serenoa repens appears to be an effective and well-tolerated pharmacologic agent in treating the mictional problems accompanying BPH.

Source: Johan Braeckman, The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study, Current Therapeutic Research, Volume 55, Issue 7, 1994, Pages 776-785, ISSN 0011-393X.

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer*

Abstract

During the last years, pharmaceutical innovations in primary care are dramatically less frequent and will be even more rare in the next future. In this context, preclinical and clinical research oriented their interest toward natural compounds efficacy and safety, supporting the development of a new "nutraceutical" science. Medicinal plants, in the form of plant parts or extracts of them, are commonly used for the treatment of prostate diseases such as benign hypertrophy, prostatitis and chronic pelvic pain syndrome. The pharmacological properties searched for the treatment of prostatic diseases are anti-androgenic, anti-estrogenic, antiproliferative, antioxidant and anti-inflammatory. The most studied and used medicinal plants are Serenoa repens, Pygeum africanum and Urtica dioica. Other promising plants are Cucurbita pepo, Epilobium spp, Lycopersum esculentum, Secale cereale, Roystonea regia, Vaccinium macrocarpon. In parallel, epidemiological studies demonstrated that diet may play an important role on incidence and development of prostatic diseases. The Mediterranean diet is rich in elements with anti-oxidant properties that act as a protective factor for prostate cancer. Similarly, low intake of animal protein, high intake of fruits and vegetables, lycopene and zinc are a protective factor for benign prostatic hyperplasia (BPH). Serenoa repens in the treatment of symptoms of BPH has been tested either alone or, more frequently, in combination with other medicinal plants, alpha-blockers and inhibitors of 5- alpha reductase (5-ARI). Recent meta-analyses found the effectiveness of Serenoa repens similar or inferior to that of finasteride and tamsulosin but clearly higher than that of placebo in the treatment of mild and moderate low urinary tract symptoms (LUTS), nocturia and discomfort. Clinical trials showed potential synergistic effects of Serenoa repens with other medicinal plants and drugs. In addition to Serenoa repens, there are many other medicinal plants for which clinical evidence is still controversial. Urtica dioica, Pygeum africanum and Curcubita pepo can be considered as an adjunct to the common therapies and their use is supported by studies showing improvement of symptoms and flowmetric indices. Lycopene and selenium are natural products with antioxidant and anti-inflammatory action. The combination of lycopene and selenium with Serenoa repens was able to reduce inflammation in histological prostate sections and to further improve symptom scores and urinary flow in patients with BPH on tamsulosin treatment. Similar effects could be obtained with the use of other carotenoids, such as astaxanthin, and/or zinc. Efficacy on symptoms of patients with BPH of some polyphenols such as quercetin, equol and curcumin have been demonstrated by clinical studies. Pollen extract is a mixture of natural components able to inhibit several cytokines and prostaglandin and leukotriene synthesis resulting in a potent anti-inflammatory effect. Pollen extracts significantly improve symptoms, pain, and quality of life in patients affected by chronic pelvic pain syndrome and chronic prostatitis. Beta-sitosterol is a sterol able to improve urinary symptoms and flow measures, but not to reduce the size of the prostate gland. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide-signaling molecule with anti-inflammatory and neuroprotective effects that can have an interesting role in the management of chronic pelvic pain syndrome and chronic urological pain. Finally, several plant-based products have been subjected to preclinical, in vitro and in vivo, investigations for their potential pharmacological activity against prostate cancer. Some epidemiological studies or clinical trials evaluated the effects of beverages, extracts or food preparations on the risk of prostate cancer. Some plant species deserved more intense investigation, such as Camelia sinensis (green or black tea), Solanum lycopersicum (common tomato), Punica granatum (pomegranate), Glycine max (common soy) and Linum usitatissimum (linen).

Source: Cicero AFG, Allkanjari O, Busetto GM, Cai T, Larganà G, Magri V, Perletti G, Robustelli Della Cuna FS, Russo GI, Stamatiou K, Trinchieri A, Vitalone A. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. 2019 Oct 2;91(3). doi: 10.4081/aiua.2019.3.139. PMID: 31577095.

Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia*

Abstract

Saw palmetto (SP), a botanical extract with antiandrogenic properties, has gained commercial popularity for its purported benefits on hair regrowth. To summarize published evidence on the efficacy, safety, and tolerability of supplements containing SP in the treatment of alopecia, we conducted a PubMed, Google Scholar, and Cochrane database search using the following terms: (saw palmetto and hair loss), (saw palmetto and androgenetic alopecia), and (saw palmetto and natural supplement and alopecia). Five randomized clinical trials (RCTs) and 2 prospective cohort studies demonstrated positive effects of topical and oral supplements containing SP (100–320 mg) among patients with androgenetic alopecia (AGA) and telogen effluvium. Sixty percent improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3% of patients, and stabilized disease progression among 52% were noted with use of various topical and oral SP-containing supplements. SP was well tolerated and not associated with serious adverse events in alopecia patients. Although robust high-quality data are lacking, supplements containing SP may be a treatment option for patients with AGA, telogen effluvium, and self-perceived hair thinning. Further large-scale RCTs focusing on the sole contribution of SP to hair growth outcomes are needed to confirm efficacy and determine long-term adverse events.

Source: Evron E, Juhasz M, Babadjouni A, Mesinkovska NA. Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia. Skin Appendage Disord. 2020 Nov;6(6):329-337. doi: 10.1159/000509905. Epub 2020 Aug 23. PMID: 33313047; PMCID: PMC7706486.

Pygeum africanum Extract (bark)(std. to 3% phytosterols)*

Pygeum africanum for benign prostatic hyperplasia*

Abstract

Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. The extract of the African prune tree, Pygeum africanum, is one of the several phytotherapeutic agents available for the treatment of BPH.

Source: Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;1998(1):CD001044. doi: 10.1002/14651858.CD001044. PMID: 11869585; PMCID: PMC7032619.

Pygeum*

Abstract

Introduction: The bark of the African plum tree (Pygeum africanum, also known as Prunus africana) has been used traditionally for the discomfort of benign prostatic hypertrophy (BPH) by the Zulu people of Africa.[1] Other peoples of Africa and Madagascar use the bark for generalized urinary-tract troubles, fever, stomach ache, and "madness" and as an aphrodisiac.[2] The hydrocyanic acid content conveys a pleasant almond flavor, and milk-based infusions are sometimes substituted for almond milk (used for drinking and cooking).[2]

Use: Currently, pygeum extract is the most popular treatment for symptoms of BPH in France and is commonly used for this condition in Italy and the United States. Compared with many other popular botanical treatments, pygeum has been fairly well researched; however, it is not mentioned in the German Commission E monographs [3,4] or in several other common botanical medicine references

Improvement in or elimination of secondary subjective outcome measures of hesitancy, weak urine stream, night-time dribbling, and feeling of residual urine was reported by 55.8-62.0% of the patients in the pygeum group and 33.3- 43.2% of the placebo recipients. Intermittent urine stream, another secondary outcome measure, showed the least improvement (35.2% of pygeum recipients and 26.9% of placebo recipients). Both physicians and patients rated pygeum treatment as generally successful in 65.6% of cases, compared with success rates of 30.8% and 40.7% in the placebo group as rated by physicians and patients, respectively. Four patients in each group dropped out of the study. Diarrhea, constipation, dizziness, stomach pains, and blurred vision were reported for three pygeum-treated patients who withdrew. Mild, transient diarrhea was reported after the study by two other pygeum recipients and two patients in the placebo group. Laboratory test values showed no significant changes. The authors concluded that the risk-to-benefit ratio supports the use of pygeum extract for treating the symptoms of BPH. The objective outcome measures used in this trial are fairly standard for assessing the severity of BPH; however, symptoms were not assessed with a validated scale. All outcome measures were compared between the groups after treatment was completed. Change from baseline was statistically compared for MFR only. Information on the statistical power of the study was not provided. The fact that the inclusion criteria had specific requirements for only one objective symptom — nocturia — raises the question of whether the sample was representative of the population of patients with BPH. Although providing some solid information, the study cannot be considered definitive. Definitive results were also not provided by two more recent trials, since they did not have placebo or active-treatment controls. Breza and colleagues 24 used pygeum extract (Tadenan) 50 mg twice daily in an open-label, multicenter trial of two months' duration. Patients (n = 85) were men 50-75 years of age with at least a six-month history of urinary-tract problems and an IPSS of 12. The primary endpoint was mean change from baseline in IPSS at two months. Secondary endpoints included mean change from baseline in the frequency of nocturia and mean change from baseline in QOL score. Objective assessments included MFR, average flow rate and volume, residual volume, and prostate volume. The researchers found a significant decrease of 40% in mean IPSS and a significant increase of 31% in mean QOL score at two months. The mean frequency of nocturia decreased from 2.62 to 1.66 (p < 0.001). Studies of both good and poor quality have shown that pygeum decreases BPH symptoms more than placebo, but none of the trials to date provides conclusive evidence of efficacy. Patients with mild BPH (IPSS, 7) or moderate BPH (8-18) frequently choose "watchful waiting" or alternative therapies (including herbal therapies) over standard drug therapy or surgery. The very good tolerability of pygeum and the lack of toxicity support the use of pygeum extract as an adjunctive treatment for patients with mild to moderate symptomatic BPH. The minimal effect of pygeum on prostate volume suggests that it might not be as useful for patients with greatly enlarged prostates, whose symptoms are primarily obstructive. Patients who choose to try pygeum should be counseled that it is for mild to moderate symptoms of BPH, that they must first visit a physician to rule out prostate cancer, and that the recommended dosage is 100-200 mg of standardized extract given in one or two doses daily.

Source: American Journal of Health-System Pharmacy, 2001;58(2)

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer

Abstract

During the last years, pharmaceutical innovations in primary care are dramatically less frequent and will be even more rare in the next future. In this context, preclinical and clinical research oriented their interest toward natural compounds efficacy and safety, supporting the development of a new "nutraceutical" science. Medicinal plants, in the form of plant parts or extracts of them, are commonly used for the treatment of prostate diseases such as benign hypertrophy, prostatitis and chronic pelvic pain syndrome. The pharmacological properties searched for the treatment of prostatic diseases are anti-androgenic, anti-estrogenic, antiproliferative, antioxidant and anti-inflammatory. The most studied and used medicinal plants are Serenoa repens, Pygeum africanum and Urtica dioica. Other promising plants are Cucurbita pepo, Epilobium spp, Lycopersum esculentum, Secale cereale, Roystonea regia, Vaccinium macrocarpon. In parallel, epidemiological studies demonstrated that diet may play an important role on incidence and development of prostatic diseases. The Mediterranean diet is rich in elements with anti-oxidant properties that act as a protective factor for prostate cancer. Similarly, low intake of animal protein, high intake of fruits and vegetables, lycopene and zinc are a protective factor for benign prostatic hyperplasia (BPH). Serenoa repens in the treatment of symptoms of BPH has been tested either alone or, more frequently, in combination with other medicinal plants, alpha-blockers and inhibitors of 5- alpha reductase (5-ARI). Recent meta-analyses found the effectiveness of Serenoa repens similar or inferior of that of finasteride and tamsulosin but clearly higher than that of placebo in the treatment of mild and moderate low urinary tract symptoms (LUTS), nocturia and discomfort. Clinical trials showed potential synergistic effects of Serenoa repens with other medicinal plants and drugs. In addition to Serenoa repens, there are many other medicinal plants for which clinical evidence is still controversial. Urtica dioica, Pygeum africanum and Curcubita pepo can be considered as an adjunct to the common therapies and their use is supported by studies showing improvement of symptoms and flowmetric indices. Lycopene and selenium are natural products with antioxidant and anti-inflammatory action. The combination of lycopene and selenium with Serenoa repens was able to reduce inflammation in histological prostate sections and to further improve symptom scores and urinary flow in patients with BPH on tamsulosin treatment. Similar effects could be obtained with the use of other carotenoids, such as astaxanthin, and/or zinc. Efficacy on symptoms of patients with BPH of some polyphenols such as quercitin, equol and curcumin have been demonstrated by clinical studies. Pollen extract is a mixture of natural components able to inhibit several cytokines and prostaglandin and leukotriene synthesis resulting in a potent anti-inflammatory effect. Pollen extracts significantly improve symptoms, pain, and quality of life in patients affected by chronic pelvic pain syndrome and chronic prostatitis. Beta-sitosterol is a sterol able to improve urinary symptoms and flow measures, but not to reduce the size of the prostate gland. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide-signaling molecule with anti-inflammatory and neuroprotective effects that can have an interesting role in the management of chronic pelvic pain syndrome and chronic urological pain. Finally, several plant-based products have been subjected to preclinical, in vitro and in vivo, investigations for their potential pharmacological activity against prostate cancer. Some epidemiological studies or clinical trials evaluated the effects of beverages, extracts or food preparations on the risk of prostate cancer. Some plant species deserved more intense investigation, such as Camelia sinensis (green or black tea), Solanum lycopersicum (common tomato), Punica granatum (pomegranate), Glycine max (common soy) and Linum usitatissimum (linen).

Stinging Nettle (Urtica dioica) root extract

A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix*

Abstract

Nettle root is recommended for complaints associated with benign prostatic hyperplasia (BPH). We therefore conducted a comprehensive review of the literature to summarise the pharmacological and clinical effects of this plant material. Only a few components of the active principle have been identified and the mechanism of action is still unclear. It seems likely that sex hormone binding globulin (SHBG), aromatase, epidermal growth factor and prostate steroid membrane receptors are involved in the anti-prostatic effect, but less likely that 5alpha-reductase or androgen receptors are involved. Extract and a polysaccharide fraction were shown to exert anti-inflammatory activity. A proprietary methanolic nettle root extract and particular fractions inhibited cell proliferation. Isolated lectins (UDA) were shown to be promising immunomodulatory agents, having also anti-viral and fungistatic effects. However, despite these in vitro studies it is unclear whether the in-vitro or animal data are a surrogate for clinical effects. The clinical evidence of effectiveness for nettle root in the treatment of BPH is based on many open studies. A small number of randomised controlled studies indicate that a proprietary methanolic extract is effective in improving BPH complaints. However, the significance and magnitude of the effect remains to be established in further confirmatory studies before nettle root treatment may be accepted in the guidelines for BPH treatment. The risk for adverse events during nettle root treatment is very low, as is its toxicity. Pre-clinical safety data remain to be completed.

Source: Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007 Aug;14(7-8):568-79. doi: 10.1016/j.phymed.2007.03.014. Epub 2007 May 16. PMID: 17509841.

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer*

Abstract

During the last years, pharmaceutical innovations in primary care are dramatically less frequent and will be even more rare in the next future. In this context, preclinical and clinical research oriented their interest toward natural compounds efficacy and safety, supporting the development of a new "nutraceutical" science. Medicinal plants, in the form of plant parts or extracts of them, are commonly used for the treatment of prostate diseases such as benign hypertrophy, prostatitis and chronic pelvic pain syndrome. The pharmacological properties searched for the treatment of prostatic diseases are anti-androgenic, anti-estrogenic, antiproliferative, antioxidant and anti-inflammatory. The most studied and used medicinal plants are Serenoa repens, Pygeum africanum and Urtica dioica. Other promising plants are Cucurbita pepo, Epilobium spp, Lycopersum esculentum, Secale cereale, Roystonea regia, Vaccinium macrocarpon. In parallel, epidemiological studies demonstrated that diet may play an important role on incidence and development of prostatic diseases. The Mediterranean diet is rich of elements with anti-oxidant properties that act as a protective factor for prostatic cancer. Similarly, low intake of animal protein, high intake of fruits and vegetables, lycopene and zinc are a protective factor for benign prostatic hyperplasia (BPH). Serenoa repens in the treatment of symptoms of BPH has been tested either alone or, more frequently, in combination with other medicinal plants, alpha-blockers and inhibitors of 5- alpha reductase (5-ARI). Recent meta-analyses found the effectiveness of Serenoa repens similar or inferior of that of finasteride and tamsulosin but clearly higher than that of placebo in the treatment of mild and moderate low urinary tract symptoms (LUTS), nocturia and discomfort. Clinical trials showed potential synergistic effect of Serenoa repens with other medicinal plants and drugs. In addition to Serenoa repens, there are many other medicinal plants for which clinical evidence is still controversial. Urtica dioica, Pygeum africanum and Curcubita pepo can be considered as an adjunct to the common therapies and their use is supported by studies showing improvement of symptoms and flowmetric indices. Lycopene and selenium are natural products with antioxidant and anti-inflammatory action. The combination of lycopene and selenium with Serenoa repens was able to reduce inflammation in histological prostate sections and to further improve symptom scores and urinary flow in patients with BPH on tamsulosin treatment. Similar effects could be obtained with the use of other carotenoids, such as astaxanthin, and/or zinc. Efficacy on symptoms of patients with BPH of some polyphenols such as quercitin, equol and curcumin have been demonstrated by clinical studies. Pollen extract is a mixture of natural components able to inhibit several cytokines and prostaglandin and leukotriene synthesis resulting in a potent anti-inflammatory effect. Pollen extracts significantly improve symptoms, pain, and quality of life in patients affected by chronic pelvic pain syndrome and chronic prostatitis. Beta-sitosterol is a sterol able to improve urinary symptoms and flow measures, but not to reduce the size of the prostate gland. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide-signaling molecule with anti-inflammatory and neuroprotective effects that can have an interesting role in the management of chronic pelvic pain syndrome and chronic urological pain. Finally, several plant-based products have been subjected to preclinical, in vitro and in vivo, investigations for their potential pharmacological activity against prostate cancer. Some epidemiological studies or clinical trials evaluated the effects of beverages, extracts or food preparations on the risk of prostate cancer. Some plant species deserved more intense investigation, such as Camelia sinensis (green or black tea), Solanum lycopersicum (common tomato), Punica granatum (pomegranate), Glycine max (common soy) and Linum usitatissimum (linen).

Lycopene 5% (Lycopersicum esculentum)

Lycopene Inhibits the Growth of Normal Human Prostate Epithelial Cells in Vitro*

Abstract

Lycopene has repeatedly been shown to inhibit the growth of human prostate cells in vitro. However, previous studies with lycopene have focused on cancer specimens, and it is still unclear whether this carotenoid affects the growth of normal human prostate cells as well. Therefore, we investigated the effects of lycopene on normal human prostate epithelial cells (PrEC) by treating them with synthetic all-E-lycopene (up to 5 μmol/L) and assessing proliferation via [3H]thymidine incorporation. The effects of lycopene on cell cycle progression were investigated via flow cytometry. To elucidate whether lycopene modulates cyclins involved in cell cycle progression, protein expressions of cyclins D1 and E were analyzed. The results show that lycopene significantly inhibited the growth of PrEC in a dose-dependent fashion. Flow cytometry revealed a significant cell cycle arrest in the G0/G1 phase. This effect was confirmed by inhibition of cyclin D1 protein expression, whereas cyclin E levels remained unchanged. The results demonstrate that lycopene inhibits growth of nonneoplastic PrEC in vitro. We hypothesize that lycopene might likewise inhibit the growth of prostatic epithelial cells in vivo. This might have an effect on prostate development and/or on enlargement of prostate tissue as found in benign prostate hyperplasia, a potential precursor of prostate cancer.

Source: Ute C. Obermüller-Jevic, Estibaliz Olano-Martin, Ana M. Corbacho, Jason P. Eiserich, Albert van der Vliet, Giuseppe Valacchi, Carroll E. Cross, Lester Packer, Lycopene Inhibits the Growth of Normal Human Prostate Epithelial Cells in Vitro, The Journal of Nutrition, Volume 133, Issue 11, November 2003, Pages 3356–3360, https://doi.org/10.1093/jn/133.11.3356.

French Maritime Pine Bark Extract (Pinus pinaster)

Effects of a supplement combining Pycnogenol® and l-arginine aspartate on lower urinary dysfunction compared with saw palmetto extract*

Abstract

Objective: Lower urinary tract symptoms (LUTS) and sexual dysfunction (SDys) are common problems that affect quality of life (QOL) in elderly men. In addition to prescribed drugs, many over-the-counter medications including supplements are used to treat QOL diseases. Phosphodiesterase inhibitors are reported to be effective for both LUTS and SDys by increasing nitric oxide levels. French maritime pine bark extract Pycnogenol®, which is a potent nitric oxide donor, is reported to be effective for SDys. However, no reports have been published on whether it ameliorates LUTS.

Design: Open-labeled, randomized study. The effects of two supplements, Nokogiriyashi EX® containing 160 mg saw palmetto (SP) extract per tablet and Edicare® containing 10 mg of Pycnogenol®, 115 mg of l-arginine and 92 mg of aspartate (PAA) per tablet on International Prostate Symptom Score (IPSS), IPSS–QOL, Overactive Bladder Symptom Score (OABSS), International Index of Erectile Function 5 (IIEF5), Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), urinary 8-OHdG and uroflowmetry (UFM) of total 40 men with LUTS and SDys were examined.

Results: 19 subjects were instructed to take two tablets of SP, on the other 20 were on four tablets of PAA for 16 weeks. IPSS and IPSS–QOL showed statistically significant improvements in both groups. OABSS and IIEF5 were significantly improved in the PAA group. Conversely, ICIQ-SF, 8-OHdG and UFM did not change in either group.

Conclusion: PAA might be an effective therapeutic alternative for elderly patients with LUTS and SDys.

Source: Yagi H, Sato R, Nishio K, Arai G, Soh S, Okada H. Effects of a supplement combining Pycnogenol® and l-arginine aspartate on lower urinary dysfunction compared with saw palmetto extract. J Tradit Complement Med. 2016 Jun 11;7(1):117-120. doi: 10.1016/j.jtcme.2016.05.008. PMID: 28053897; PMCID: PMC5198833.

Selenium

(same study again: Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer)

PROSTA-LUX

CLINICAL STUDIES ON THE FOLLOWING INGREDIENTS:

Saw Palmetto

Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia*

Abstract

The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study*

Abstract

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer*

Abstract

Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia*

Abstract

Pygeum africanum Extract (bark)(std. to 3% phytosterols)*

Pygeum africanum for benign prostatic hyperplasia*

Abstract

Pygeum*

Abstract

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer

Abstract

Stinging Nettle (Urtica dioica) root extract

A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix*

Abstract

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer*

Abstract

Lycopene 5% (Lycopersicum esculentum)

Lycopene Inhibits the Growth of Normal Human Prostate Epithelial Cells in Vitro*

Abstract

French Maritime Pine Bark Extract (Pinus pinaster)

Effects of a supplement combining Pycnogenol® and l-arginine aspartate on lower urinary dysfunction compared with saw palmetto extract*

Abstract

Selenium

References: